Decera Clinical Education Infectious Disease Podcast

In this podcast episode, Sharon R. Lewin, AO, FRACP, PhD, FAHMS, and Arthur Kim, MD, discuss data on the potential use of monoclonal antibodies (mAb) for the prevention and treatment of COVID-19, including: Rationale for use of mAb Potential for resistance to mAb Single vs combination therapy with mAb Challenges in implementation of mAb as treatment or prevention Bamlanivimab Sotrovimab Casirivima...

In this first of 2 episodes, Shobha Swaminathan, MD, and Eric S. Daar, MD, review key data influencing their practice following the IAS 2021 Conference, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB plus RPV for ART in treatment-naive PWH.   This episode includes discussion of: A Global Clinical Platform that evaluated out...

In this series of 3 episodes, Geeta Gupta, MD, discusses strategies for optimizing ART in heavily treatment–experienced patients with HIV, including management of virologic failure and switching ART in virologically suppressed patients with underlying resistance. The 3 episodes will include analyses from: BENCHMRK, which demonstrated that the number of active drugs predicts outcomes in treatment-e...

In this episode, Mindie H. Nguyen, MD, MAS, AGAF, FAASLD, and Lewis R. Roberts, MB ChB, PhD, examine the HBV burden and care disparities in specific populations, including Asian Americans and foreign-born immigrants, and strategies to address barriers to care. Presenters: Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Professor of Medicine Department of Gastroenterology and Hepatology Stanford University...

In this series of 3 episodes, Geeta Gupta, MD, discusses strategies for optimizing ART in heavily treatment–experienced patients with HIV, including management of virologic failure and switching ART in virologically suppressed patients with underlying resistance. The 3 episodes will include analyses from: BENCHMRK, which demonstrated that the number of active drugs predicts outcomes in treatment-e...

In this series of 3 episodes, Geeta Gupta, MD, discusses strategies for optimizing ART in heavily treatment–experienced patients with HIV, including management of virologic failure and switching ART in virologically suppressed patients with underlying resistance. The 3 episodes will include analyses from: BENCHMRK, which demonstrated that the number of active drugs predicts outcomes in treatment-e...

In this episode, Joseph J. Eron, Jr., MD, explores whether weight gain should or should not be a factor in determining initial therapy. Listen as he gives his perspectives on: Weight gain following ART initiation by ARV class and ARV drug Results of the ADVANCE and GEMINI-1 and -2 studies, with exploration of weight, risk of CVD and diabetes BMI changes in PWH DHHS and IAS-USA guidelines for initi...

In this episode, David Malebranche, MD, MPH, discusses modifying ART in virologically suppressed patients, including switching ART in a patient with daily pill fatigue, switching ART to avoid comorbidities and simplifying ART in the context of known multidrug resistance. The overview will include analyses from: The ATLAS and FLAIR studies in which long-acting intramuscular CAB + RPV was initiated...

In this episode, Paul E. Sax, MD, discusses emerging drug therapies and treatment options for patients with HIV, including rapid initiation of ART, long-acting ART, and 2-drug ART regimens. The overview will include analyses from: The RAPID ART program in San Francisco, where same-day initiation of ART led to faster HIV-1 RNA suppression that was maintained at greater than 92% during a 3-year peri...

In this episode, Jennifer Cocohoba, PharmD, and Jason Schafer, PharmD, MPH, discuss key studies from IAS 2021 that will influence the role of the pharmacist in the treatment and prevention of HIV. Their discussion includes analyses of: The 144-week analysis of the TANGO study, showing high rates of virologic suppression of patients switched from a TAF-containing regimen to DTG plus 3TC The 144-wee...

In this episode, Babafemi Taiwo, MBBS, discusses new HIV data from IAS 2021, including: WHO Global Clinical Platform: COVID-19 outcomes in PWH 2-drug regimen of DTG/3TC: efficacy, metabolic outcomes (TANGO) Investigational antiretroviral use CAB LA + RPV LA in treatment-naive PWH (FLAIR) Investigational antiretroviral agents LEN (CAPELLA, CALIBRATE) ISL (P011, P016) Alternative BPaL dosing in trea...

During this episode, Darrell H. S. Tan, MD, FRCPC, PhD, discusses approved and guideline-recommended oral HIV PrEP regimens and provides key insights on determining PrEP candidacy as well as important considerations for specific populations/clinical scenarios, including adolescents, pregnancy/breastfeeding, and transgender individuals. Presenter: Darrell H. S. Tan, MD, FRCPC, PhD Associate Profess...

In episode 5 of an ongoing series of sharing sessions between a physician and patient, Anna Christina L. dela Cruz, MD, and Rhonda, who is living with chronic hepatitis B, discuss what to do when the decision to start treatment is not clear because of borderline ALT test results and HBV DNA levels. Their conversation highlights a need for patient education and shared decision-making. Presenter: An...

In episode 4 of an ongoing series of sharing sessions between a physician and patient, Geoffrey M. Dusheiko, MD, FCP(SA), FRCP, discusses hepatitis B diagnosis and treatment with his patient, Mark. The conversation focuses on Mark’s missed HBV diagnosis and likely reactivation following treatment for rheumatoid arthritis and raises awareness for needed improvements to communication between multidi...

In this episode, Oluwaseun Falade-Nwulia, MBBS, MPH, and Joseph K. Lim, MD, examine the HCV burden and care disparities in specific populations, including Black, Hispanic, Asian, American Indian, and Alaska Native persons, and strategies to address barriers to care. Oluwaseun Falade-Nwulia, MBBS, MPH Associate Professor Division of Infectious Diseases Johns Hopkins University School of Medicine At...

In this episode, Stefan Zeuzem, MD, discusses exciting new data on viral hepatitis reported at the virtual EASL 2021, including new findings on treatment of HDV, treatment of HBV and HCV in children, linking patients to care, and new molecules being investigated for HBV cure. Stefan Zeuzem, MD Professor of Medicine Chief , Department of Medicine I JW Goethe University Hospital  Frankfurt, Germany...

Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable c...

In this podcast, Spencer H. Durham, PharmD, BCPS, BCIDP; Stefan Gravenstein, MD, MPH; and Barbara Resnick, PhD, CRNP, discuss risk factors for respiratory syncytial virus among adults, the need for a vaccination strategy in this population, and the evolving clinical studies on vaccines for older adults. Following their dialogue, the faculty field questions from healthcare professionals. Presenters...

Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable c...

In this episode, Jehan Budak, MD, discusses the use of HIV-ASSIST, a free, online, decision-support tool to inform ART selection. Jehan Budak, MD Assistant Professor Division of Allergy & Infectious Diseases University of Washington Seattle, Washington Content based on a CME program supported by educational grants from Gilead Sciences, Inc.; Theratechnologies; and ViiV Healthcare. Link to full pro...

In this episode, Latesha Elopre, MD, MSPH, explains how to initiate pre-exposure prophylaxis (PrEP), including in underserved communities, with examples on overcoming barriers and improving access. Listen as she gives her perspectives on: Evidence for PrEP efficacy in the DISCOVER study Recommendations in MSM, heterosexual men and women, injection drug users, and adolescents and adults weighing mo...

In this episode, Daniel J. Kuritzkes, MD, reviews key clinical trial data and gives practical insights such as how to initiate a patient on long-acting therapy, recommended dosing regimens, and factors that may increase the risk of treatment failure. The overview will include analyses of: ATLAS and FLAIR studies of long-acting injectable CAB + RPV ATLAS 2M dosing study FDA approval and DHHS statem...

In this episode, Joseph J. Eron, Jr., MD, and Darcy Wooten, MD, share insights on HIV antiretroviral therapy safety and tolerability including recent data on weight gain and metabolic implications with INSTIs and NRTIs as well as the latest updates and recommendations on dolutegravir and pregnancy. Joseph J. Eron, Jr., MD Professor of Medicine and Epidemiology University of North Carolina School o...

Listen to expert insights from Joseph J. Eron, Jr., MD, on exciting data about investigational agents (dapivirine ring, islatravir, lenacapavir, broadly neutralizing antibodies) for next-generation HIV prevention. Joseph J. Eron, Jr., MD Professor of Medicine and Epidemiology University of North Carolina School of Medicine Director , AIDS Clinical Trials Unit University of North Carolina Chapel Hi...

Produced in collaboration with the Global HIV Vaccine Enterprise at the International AIDS Society (IAS), this 4-episode podcast series features conversations between world-renowned guests in HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable c...